Preparing for 2021: Drug and Device Pricing, Payment, and Fraud and Abuse Challenges

There were a variety of important legal and regulatory developments in the final months of 2020 that will impact pharmaceutical manufacturers in 2021 and beyond. During this webinar, members of our Life Sciences & Healthcare Regulatory group review the following key developments in detail: value-based arrangements, manufacturer product support programs, manufacturer speaker programs, healthcare technology, CMS Medicaid Rebate Program final rule, and 340B Drug Pricing Program.